Patents by Inventor Lars J. S. Knutsen

Lars J. S. Knutsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for the treatment of neuromuscular disorders
    Patent number: 11730714
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: August 22, 2023
    Assignee: NMD PHARMA A/S
    Inventors: Thomas Holm Pedersen, Lars J. S. Knutsen, Nicholas M. Kelly, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen, Rajesh Kumar
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 11591284
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 28, 2023
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc A. Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj
  • COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
    Publication number: 20220388938
    Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
    Type: Application
    Filed: June 19, 2020
    Publication date: December 8, 2022
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. KNUTSEN, Nicholas KELLY, Martin Brandhøj SKOV, Anders RIISAGER, Neerja SARASWAT
  • COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
    Publication number: 20220306564
    Abstract: The present disclosure relates to compounds of Formula I: suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Application
    Filed: June 19, 2020
    Publication date: September 29, 2022
    Applicant: NMD PHARMA A/S
    Inventors: Nicholas KELLY, Lars J.S. KNUTSEN, Daniel Paul COTTON
  • 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS
    Publication number: 20220274938
    Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
    Type: Application
    Filed: June 19, 2020
    Publication date: September 1, 2022
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. KNUTSEN, Martin BROCH-LIPS, Martin E COOPER, Marc LABELLE, Thomas Holm PEDERSEN, Dastagiri DUDEKULA, Neerja SARASWAT, Rafiq A TAJ
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 11147788
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: October 19, 2021
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Thomas Holm Pedersen, Martin Broch-Lipps, Claus Elsborg Olesen, Marc Labelle, Ole Baekgaard Nielsen
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 10385028
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: August 20, 2019
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Martin E. Cooper, Andrew W. Brown
  • Compounds For The Treatment Of Neuromuscular Disorders
    Publication number: 20190183834
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 20, 2019
    Applicant: NMD PHARMA A/S
    Inventors: Thomas Holm Pedersen, Lars J.S. Knutsen, Nicholas M. Kelly, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen, Rajesh Kumar
  • Compounds For The Treatment Of Neuromuscular Disorders
    Publication number: 20190185437
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the ClC-1 ion channel.
    Type: Application
    Filed: December 14, 2017
    Publication date: June 20, 2019
    Applicant: NMD Pharma ApS
    Inventors: Lars J.S. Knutsen, Martin E. Cooper, Andrew W. Brown
  • Compounds For The Treatment Of Neuromuscular Disorders
    Publication number: 20190183833
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Application
    Filed: December 14, 2017
    Publication date: June 20, 2019
    Inventors: Lars J.S. Knutsen, Thomas Holm Pedersen, Martin Broch-Lipps, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen
  • Compounds For The Treatment Of Neuromuscular Disorders
    Publication number: 20190183863
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 20, 2019
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. Knutsen, Nicholas M. Kelly, Thomas Holm Pedersen, Martin E. Cooper, Andrew W. Brown
  • Compounds For The Treatment Of Neuromuscular Disorders
    Publication number: 20190185409
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.
    Type: Application
    Filed: December 14, 2017
    Publication date: June 20, 2019
    Applicant: NMD Pharma ApS
    Inventors: Lars J.S. Knutsen, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc A. Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj
  • Compounds For The Treatment Of Neuromuscular Disorders
    Publication number: 20190183812
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 20, 2019
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. Knutsen, Nicholas M. Kelly, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj
  • Substituted pyridazine derivatives
    Patent number: 8912183
    Abstract: The present invention is directed to compounds having histamine H3 antagonist activity, as well as methods of their use and preparation.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: December 16, 2014
    Assignee: Cephalon, Inc.
    Inventors: Robert L. Hudkins, Lars J. S. Knutsen, Catherine P. Prouty, Babu G. Sundar, Kevin J. Wells-Knecht
  • PYRIDAZINONE DERIVATIVES
    Publication number: 20140142088
    Abstract: The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.
    Type: Application
    Filed: November 18, 2013
    Publication date: May 22, 2014
    Applicant: CEPHALON, INC.
    Inventors: Edward R. Bacon, Thomas R. Bailey, Nadine C. Becknell, Sankar Chatterjee, Derek Dunn, Greg A. Hostetler, Robert L. Hudkins, Kurt A. Josef, Lars J.S. Knutsen, Ming Tao, Alison L. Zulli
  • Methods of treating disorders mediated by histamine Hreceptors using pyridazinone derivatives
    Patent number: 8673916
    Abstract: The present invention is directed to methods of treating disorders mediated by Histamine H3 receptors by administering novel pyridazinone derivatives. In particular, the pyridazinone compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: March 18, 2014
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Thomas R. Bailey, Nadine C. Becknell, Sankar Chatterjee, Derek D. Dunn, Greg A. Hostetler, Robert L. Hudkins, Kurt A. Josef, Lars J. S. Knutsen, Ming Tao, Allison L. Zulli
  • Aryl pyridazinone derivatives and their use as H3 receptor ligands
    Patent number: 8586588
    Abstract: The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds and/or their pharmaceutically acceptable salts may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: November 19, 2013
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Thomas R. Bailey, Nadine C. Becknell, Sankar Chatterjee, Derek Dunn, Greg A. Hostetler, Robert L. Hudkins, Kurt A. Josef, Lars J. S. Knutsen, Ming Tao, Allison L. Zulli
  • Pyridazinone derivatives
    Patent number: 8207168
    Abstract: The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition disorders.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: June 26, 2012
    Assignee: Cephalon, Inc.
    Inventors: Nadine C. Becknell, Derek Dunn, Robert L. Hudkins, Kurt A. Josef, Lars J. S. Knutsen, Ming Tao, Allison L. Zulli
  • Substituted Pyridazine Derivatives
    Publication number: 20120004231
    Abstract: The present invention is directed to compounds having histamine H3 antagonist activity, as well as methods of their use and preparation.
    Type: Application
    Filed: September 13, 2011
    Publication date: January 5, 2012
    Applicant: CEPHALON, INC.
    Inventors: Robert L. Hudkins, Lars J.S. Knutsen, Catherine P. Prouty, Babu G. Sundar, Kevin J. Wells-Knecht
  • Substituted pyridazine derivatives
    Patent number: 8076331
    Abstract: The present invention is directed to compounds having histamine H3 antagonist activity, as well as methods of their use and preparation.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: December 13, 2011
    Assignee: Cephalon, Inc.
    Inventors: Robert L. Hudkins, Lars J. S. Knutsen, Catherine P. Prouty, Babu G. Sundar, Kevin J. Wells-Knecht